BridgeBio has substantially advanced the development of a new therapy for cardiac amyloidosis, utilizing the compound. Initial patient results suggests significant outcomes for those suffering by the severe disease. https://attr-cm256240.humor-blog.com/40550814/firm-advances-cardiac-amyloidosis-treatment-through-attruby